ResMed Inc (RMD)
Return on equity (ROE)
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 1,400,723 | 1,313,254 | 1,248,705 | 1,112,883 | 1,020,950 | 958,378 | 890,386 | 906,500 | 897,556 | 862,953 | 809,465 | 786,302 | 779,437 | 779,474 | 521,981 | 499,744 | 474,503 | 457,240 | 698,858 | 679,898 |
| Total stockholders’ equity | US$ in thousands | 5,967,860 | 5,546,130 | 5,253,010 | 5,195,030 | 4,864,040 | 4,629,920 | 4,481,850 | 4,250,380 | 4,129,900 | 3,932,510 | 3,738,130 | 3,432,890 | 3,360,750 | 3,278,800 | 3,145,840 | 3,026,050 | 2,885,680 | 2,709,230 | 2,864,980 | 2,678,860 |
| ROE | 23.47% | 23.68% | 23.77% | 21.42% | 20.99% | 20.70% | 19.87% | 21.33% | 21.73% | 21.94% | 21.65% | 22.90% | 23.19% | 23.77% | 16.59% | 16.51% | 16.44% | 16.88% | 24.39% | 25.38% |
June 30, 2025 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $1,400,723K ÷ $5,967,860K
= 23.47%
The analysis of ResMed Inc.’s return on equity (ROE) over the specified period reveals fluctuations and trends indicative of the company's profitability relative to shareholders' equity. Starting from a high of 25.38% as of September 30, 2020, the ROE experienced a notable decline by March 31, 2021, reaching approximately 16.88%. This decrease persisted into the subsequent quarters, with values remaining in the range of approximately 16.44% to 16.59% through September 30, 2021, and December 31, 2021.
From March 31, 2022, onwards, the ROE demonstrated a recovery, climbing to around 23.77% by March 31, 2022, and maintaining this elevated level into June and September of that year. It then gradually declined in the following quarters, reaching approximately 21.65% at the end of 2022. Throughout 2023, the ROE stabilized slightly above 21%, fluctuating marginally, with values of 21.94% at March 31, 2023, and 21.33% at September 30, 2023. The data for the partial period ending December 31, 2023, shows a decrease to 19.87%, followed by a slight uptick in March and June 2024 to approximately 20.70% and 20.99%, respectively.
Looking forward, projections indicate a recovery trend toward the high 20s, with ROE expected to reach approximately 23.77% by December 2024 and sustaining near 23.68% to 23.47% into mid-2025. This pattern suggests that ResMed's ROE has experienced cyclical fluctuations, initially declining post-2020, then recovering and stabilizing through 2022 and 2023, followed by short-term declines and potential rebounds.
Overall, the company's ROE reflects periods of volatility but also demonstrates resilience with tendencies toward higher profitability margins in later periods compared to the post-2020 lows. These fluctuations could be influenced by changes in net income, equity structure, and broader business conditions affecting profitability and investor returns.
Peer comparison
Jun 30, 2025